Navigation Links
FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Candidiasis
Date:7/16/2014

NORTHBROOK, Ill., July 16, 2014 /PRNewswire/ -- Astellas today announced that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive candidiasis, a life-threatening, invasive fungal infection.

A product that is granted QIDP status receives a priority review and a five-year extension of market exclusivity in the United States. Previously, isavuconazole received QIDP designation for invasive aspergillosis and invasive mucormycosis (also known as zygomycosis). The incentives for all three conditions were granted under the 2012 U.S. Generating Antibiotic Incentives Now (GAIN) Act as a part of the FDA Safety and Innovation Act.

"The need to treat serious fungal infections can be one of life or death. This QIDP designation, along with the previous two we have received, emphasizes how important it is to patients and their families that products are available to treat these infections," said Bernie Zeiher, Executive Vice President, Global Development and Therapeutic Area Head of Infectious Disease at Astellas.

About Isavuconazole
Isavuconazole (drug substance: isavuconazonium sulfate) is an investigational once-daily intravenous and oral broad-spectrum antifungal being developed for the treatment of severe invasive and life-threatening fungal infections. Isavuconazole is the active moiety of the prodrug isavuconazonium sulfate. Information regarding isavuconazole ongoing clinical trials is available at clinicaltrials.gov.  

Isavuconazole demonstrated in-vitro and in-vivo coverage of a broad range of yeasts (such as Candida species) and molds (such as Aspergillus species) as well as activity against emerging and often fatal molds including those that cause mucormycosis.

In the Phase 3 invasive aspergillosis study, isavuconazole demonstrated non-inferiority to voriconazole on the primary endpoint of all-cause mortality at day 42.  The treatment-emergent adverse events for isavuconazole were statistically fewer relative to voriconazole in the System Organ Classes of hepatobiliary, skin and eye disorders. In both treatment groups, the most common treatment emergent adverse events were nausea, vomiting, pyrexia (fever) and diarrhea.

Isavuconazole is being co-developed with Basilea Pharmaceutica International Ltd.

About Astellas Infectious Disease
Astellas' commitment to the field of infectious diseases is an active one. We're expanding the knowledge base of this therapeutic area and empowering physicians to make evidence-based clinical decisions.

Our proud history of collaborating with investigators around the world provides ideal environments to study compounds that have the potential for significant breakthroughs and allows us to generate and publish key information on our advances. In fact, Astellas has performed some of the world's largest clinical trials in fungal infections.

About Astellas
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through provision of innovative and reliable pharmaceuticals. The headquarters for the Americas is located in Northbrook, Ill. For more information on Astellas, please visit our website at www.astellas.us.

Logo - http://photos.prnewswire.com/prnh/20140416/84970


'/>"/>
SOURCE Astellas
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Grants Orphan Drug Designation to Omeros OMS721 for Complement-Mediated Thrombotic Microangiopathies
2. FDA Grants Approval of IND to Commence a Phase 3 Pivotal Study for ST10 for the Treatment of Iron Deficiency Anaemia in Chronic Kidney Disease
3. Auxilium Pharmaceuticals, Inc. Announces Court Grants Upsher-Smith Laboratories Motion For Summary Judgment
4. FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Aspergillosis
5. RadSite Grants Accreditation to First Wave of MIPPA Program Applicants
6. NASDAQ Grants China Jo-Jo Drugstores 180-Day Extension to Regain Compliance with Bid Price Requirement
7. U.S. FDA Grants Orphan Drug Designation for KaloBios KB001-A in Treatment of Cystic Fibrosis Patients
8. FDA Grants 510(k) Clearance for Innovative Fuse Gastroscope from EndoChoice
9. Philanthropic Grants, Product Launches, Promising Partnerships, and Customer Satisfaction Rankings - Research Report on CVS Caremark, Walgreens, McKesson, AmerisourceBergen, and Cardinal Health
10. Life Technologies Awards Digital PCR Innovation Grants to Five Research Labs
11. FDA Grants Lillys Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... 13, 2017 It should come as no surprise ... is in the midst of a crippling opioid epidemic. According ... the number of overdose deaths from opiate-based medications has quadrupled, ... a million dead from 2001 to 2015". During this time, ... has similarly quadrupled, drawing a compelling link between prescription and ...
(Date:7/13/2017)... 2017 RK Logistics Group, Inc. was awarded ... its Fremont, CA headquarters facility where ... and San Jose for hi-tech, pharmaceutical ... , with its Fremont Innovation District, is excited to ... powerful resource to the hundreds of biotech, pharma and biomed ...
(Date:7/12/2017)... -- CarpalAID is a revolutionary new product that relieves painful carpal ... tunnel syndrome affects more than 8 million people a year. Women ... The common methods of treating CTS are painful surgery, the use ... gloves. ... CarpalAID is a clear patch worn on the palm of the ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... 21, 2017 , ... In the first prospective ACL reconstruction ... Outcome Network (MOON) demonstrated that patients could perform sports-related functions and maintain a ... over time. The study, presented today at the American Orthopaedic Society for ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... rates are on the rise, say researchers presenting their work at the ... Canada. , “The combination of evaluating the patterns of change in concussion symptom ...
(Date:7/20/2017)... Richmond, Va. (PRWEB) , ... July 20, 2017 , ... ... Daniel McCarter, MD, has joined JenCare Senior Medical Center as Richmond Chief ... of Virginia School of Medicine, and Associate Chief Medical Officer of Ambulatory Services for ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... and application performance monitoring (APM) solutions, has expanded its footprint inside the ... According to Peter Ohrenberger, sales director at Nastel, “We’ve replaced an existing ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... For individuals ... utmost importance. The adjustable beds used in such facilities are specially designed to accommodate ... adequate arm support. , An inventor from Rochester, Ind., has invented the patent-pending ...
Breaking Medicine News(10 mins):